Reconciliation of IP

Reconciliation of IP - Axcellant

Reconciliation of IP

  1. lut 28, 2025

What Does the 'Reconciliation of IP’ Mean?

Reconciliation of IP, in clinical research, refers to the process of accounting for all investigational product (IP) throughout a clinical trial. This involves tracking the quantity of IP received, dispensed, returned, and destroyed, ensuring that all units are accounted for and any discrepancies are identified and explained.

The reconciliation process is crucial for maintaining regulatory compliance and ensuring the integrity of clinical trial data. It typically occurs at regular intervals during the study and at the conclusion of the trial, with the aim of verifying that the IP has been handled and administered according to the study protocol.

Why Is the 'Reconciliation of IP’ Important in Clinical Research?

Reconciliation of IP is crucial for maintaining the integrity and validity of clinical trial data. It ensures that all investigational products are properly accounted for, which is essential for regulatory compliance and the accurate assessment of drug efficacy and safety.

This process also helps in detecting and preventing potential errors or misconduct in drug handling and administration. By providing a clear audit trail, reconciliation of IP supports the overall quality and credibility of the clinical research, which is vital for the eventual approval and marketing of new drugs.

Good Practices and Procedures

  1. Implement a barcode or RFID system for real-time tracking of IP units throughout the supply chain
  2. Conduct blind counts by independent monitors to verify site-reported IP quantities
  3. Utilize temperature-logging devices to ensure proper storage conditions and flag potential deviations
  4. Perform periodic cross-checks between electronic data capture systems and physical inventory logs
  5. Establish a standardized reconciliation schedule with increasing frequency as the study progresses

Related Terms

Read more

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…

Axcellant at EANM 2025: What We Brought Back from Barcelona

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…